{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:27:42Z","timestamp":1791336462984,"version":"4.3.1"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/nrd3869","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T10:41:47Z","timestamp":1352112107000},"page":"833-846","source":"Crossref","is-referenced-by-count":261,"title":["Drug repositioning for Alzheimer's disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Anne","family":"Corbett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Dunnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Edison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim J.","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Katona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kehoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Mudher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Passmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"key":"BFnrd3869_CR1","volume-title":"World Alzheimer Report 2010: The Global Economic Impact of Dementia","author":"A Wimo","year":"2011","unstructured":"Wimo, A. & Prince, M. World Alzheimer Report 2010: The Global Economic Impact of Dementia (Alzheimer's Disease International, 2011)."},{"key":"BFnrd3869_CR2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Rev. Drug Discov. 10, 698\u2013712 (2011).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3869_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","volume":"142","author":"LM Ittner","year":"2010","unstructured":"Ittner, L. M. et al. Dendritic function of tau mediates amyloid-\u03b2 toxicity in Alzheimer's disease mouse models. Cell 142, 387\u2013397 (2010).","journal-title":"Cell"},{"key":"BFnrd3869_CR4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard, C. et al. Alzheimer's disease. Lancet 377, 1019\u20131031 (2011).","journal-title":"Lancet"},{"key":"BFnrd3869_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1586\/ern.11.13","volume":"11","author":"C Ballard","year":"2011","unstructured":"Ballard, C., Corbett, A. & Sharp, S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev. Neurother. 11, 327\u2013329 (2011).","journal-title":"Expert Rev. Neurother."},{"key":"BFnrd3869_CR6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"GK Wilcock","year":"2008","unstructured":"Wilcock, G. K. et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483\u2013493 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR7","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green, R. C. et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557\u20132564 (2009).","journal-title":"JAMA"},{"key":"BFnrd3869_CR8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2010-100174","volume":"21","author":"ST Zhang","year":"2010","unstructured":"Zhang, S. T., Hedskog, L., Petersen, C. A. H., Winblad, B. & Ankarcrona, M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J. Alzheimers Dis. 21, 389\u2013402 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/17460441.2012.645534","volume":"7","author":"G D'Onofrio","year":"2012","unstructured":"D'Onofrio, G. et al. Advances in the identification of \u03b3-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opin. Drug Discov. 7, 19\u201337 (2012).","journal-title":"Expert Opin. Drug Discov."},{"key":"BFnrd3869_CR10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999).","journal-title":"Nature"},{"key":"BFnrd3869_CR11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes, C. et al. Long-term effects of A\u03b242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216\u2013223 (2008).","journal-title":"Lancet"},{"key":"BFnrd3869_CR12","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1073\/pnas.0813404106","volume":"106","author":"DR Thakker","year":"2009","unstructured":"Thakker, D. R. et al. Intracerebroventricular amyloid-\u03b2 antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl Acad. Sci. USA 106, 4501\u20134506 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3869_CR13","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway, S. et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061\u20132070 (2009).","journal-title":"Neurology"},{"key":"BFnrd3869_CR14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734\u2013746 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702\u2013716 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR16","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd3869_CR17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nature Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3869_CR18","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher, G., Haider, M. & Okun, M. S. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78, 1096\u20131099 (2012).","journal-title":"Neurology"},{"key":"BFnrd3869_CR19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.45.6.1161","volume":"45","author":"T Yoshitake","year":"1995","unstructured":"Yoshitake, T. et al. Incidence and risk-factors of vascular dementia and Alzheimers-disease in a defined elderly japanese population \u2014 the Hisayama study. Neurology 45, 1161\u20131168 (1995).","journal-title":"Neurology"},{"key":"BFnrd3869_CR20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","volume":"347","author":"I Skoog","year":"1996","unstructured":"Skoog, I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141\u20131145 (1996).","journal-title":"Lancet"},{"key":"BFnrd3869_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0197-4580(00)00096-8","volume":"21","author":"LJ Launer","year":"2000","unstructured":"Launer, L. J. et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21, 49\u201355 (2000).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3869_CR22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/WNL.58.8.1175","volume":"58","author":"HB Posner","year":"2002","unstructured":"Posner, H. B. et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 58, 1175\u20131181 (2002).","journal-title":"Neurology"},{"key":"BFnrd3869_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(05)70141-1","volume":"4","author":"C Qiu","year":"2005","unstructured":"Qiu, C., Winblad, B. & Fratiglioni, L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4, 487\u2013499 (2005).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/msj.20155","volume":"77","author":"DL Dickstein","year":"2010","unstructured":"Dickstein, D. L. et al. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J. Med. 77, 82\u2013102 (2010).","journal-title":"Mt Sinai J. Med."},{"key":"BFnrd3869_CR25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.1997.03540340047031","volume":"277","author":"DA Snowdon","year":"1997","unstructured":"Snowdon, D. A. et al. Brain infarction and the clinical expression of Alzheimer disease \u2014 the nun study. JAMA 277, 813\u2013817 (1997).","journal-title":"JAMA"},{"key":"BFnrd3869_CR26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tins.2009.07.006","volume":"32","author":"PG Kehoe","year":"1997","unstructured":"Kehoe, P. G., Miners, J. S. & Love, S. Angiotensins in Alzheimer's disease \u2014 friend or foe? Trends Neurosci. 32, 619\u2013628 (1997).","journal-title":"Trends Neurosci."},{"key":"BFnrd3869_CR27","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.3233\/JAD-2012-111376","volume":"30","author":"PG Kehoe","year":"2012","unstructured":"Kehoe, P. G. & Passmore, P. A. The renin\u2013angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J. Alzheimers Dis. 30, S251\u2013S269 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.07.001","volume":"95","author":"JW Wright","year":"2011","unstructured":"Wright, J. W. & Harding, J. W. Brain renin-angiotensin \u2014 a new look at an old system. Prog. Neurobiol. 95, 49\u201367 (2011).","journal-title":"Prog. Neurobiol."},{"key":"BFnrd3869_CR29","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.jhh.1001442","volume":"16","author":"J Culman","year":"2002","unstructured":"Culman, J., Blume, A., Gohlke, P. & Unger, T. The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers. J. Hum. Hypertens. 16, S64\u2013S70 (2002).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrd3869_CR30","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1172\/JCI31547","volume":"117","author":"J Wang","year":"2007","unstructured":"Wang, J. et al. Valsartan lowers brain \u03b2-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393\u20133402 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3869_CR31","first-page":"197","volume":"3","author":"L Ferrington","year":"2011","unstructured":"Ferrington, L. et al. Angiotensin II-inhibiting drugs have no effect on intraneuronal A\u03b2 or oligomeric A\u03b2 levels in a triple transgenic mouse model of Alzheimer's disease. Am. J. Transl. Res. 3, 197\u2013208 (2011).","journal-title":"Am. J. Transl. Res."},{"key":"BFnrd3869_CR32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nbd.2007.01.004","volume":"26","author":"ML Hemming","year":"2007","unstructured":"Hemming, M. L., Selkoe, D. J. & Farris, W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid \u03b2-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 26, 273\u2013281 (2007).","journal-title":"Neurobiol. Dis."},{"key":"BFnrd3869_CR33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.109.138586","volume":"54","author":"S Takeda","year":"2009","unstructured":"Takeda, S. et al. Angiotensin receptor blocker prevented \u03b2-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54, 1345\u20131352 (2009).","journal-title":"Hypertension"},{"key":"BFnrd3869_CR34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","volume":"375","author":"M Mogi","year":"2008","unstructured":"Mogi, M. et al. Telmisartan prevented cognitive decline partly due to PPAR-\u03b3 activation. Biochem. Biophys. Res. Commun. 375, 446\u2013449 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrd3869_CR35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/rej.2009.0944","volume":"13","author":"L Danielyan","year":"2010","unstructured":"Danielyan, L. et al. Protective effects of intranasal losartan in the APP\/PS1 transgenic mouse model of Alzheimer disease. Rejuven. Res. 13, 195\u2013201 (2010).","journal-title":"Rejuven. Res."},{"key":"BFnrd3869_CR36","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"N-C Li","year":"2010","unstructured":"Li, N.-C. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465 (2010).","journal-title":"BMJ"},{"key":"BFnrd3869_CR37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JAD-2011-110347","volume":"26","author":"NM Davies","year":"2011","unstructured":"Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y. & Martin, R. M. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimers Dis. 26, 699\u2013708 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","volume":"10","author":"C Anderson","year":"2011","unstructured":"Anderson, C. et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 10, 43\u201353 (2011).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell, H. et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 21, 875\u2013886 (2003).","journal-title":"J. Hypertens."},{"key":"BFnrd3869_CR40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjhyper.2005.02.013","volume":"18","author":"I Skoog","year":"2005","unstructured":"Skoog, I. et al. Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: study on cognition and prognosis in the elderly (SCOPE). Am. J. Hypertens. 18, 1052\u20131059 (2005).","journal-title":"Am. J. Hypertens."},{"key":"BFnrd3869_CR41","first-page":"281","volume":"9","author":"K Landmark","year":"1995","unstructured":"Landmark, K. et al. Nitrendipine and mefruside in elderly hypertensives \u2014 effects on blood-pressure, cardiac-output, cerebral blood-flow and metabolic parameters. J. Hum. Hypertens. 9, 281\u2013285 (1995).","journal-title":"J. Hum. Hypertens."},{"key":"BFnrd3869_CR42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNM.0b013e32804c58aa","volume":"28","author":"H Hanyu","year":"2007","unstructured":"Hanyu, H. et al. Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nuclear Med. Commun. 28, 281\u2013287 (2007).","journal-title":"Nuclear Med. Commun."},{"key":"BFnrd3869_CR43","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/bja\/65.4.514","volume":"65","author":"M Forsman","year":"1990","unstructured":"Forsman, M., Olsnes, B. T., Semb, G. & Steen, P. A. Effects of nimodipine on cerebral blood flow and neuropsychological outcome after cardiac surgery. Br. J. Anaesth. 65, 514\u2013520 (1990).","journal-title":"Br. J. Anaesth."},{"key":"BFnrd3869_CR44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2009-0925","volume":"16","author":"W Zhao","year":"2009","unstructured":"Zhao, W. et al. Identification of antihypertensive drugs which inhibit amyloid-\u03b2 protein oligomerization. J. Alzheimers Dis. 16, 49\u201357 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2011.03.048","volume":"659","author":"C Bachmeier","year":"2011","unstructured":"Bachmeier, C., Beaulieu-Abdelahad, D., Mullan, M. & Paris, D. Selective dihydropyiridine compounds facilitate the clearance of \u03b2-amyloid across the blood\u2013brain barrier. Eur. J. Pharmacol. 659, 124\u2013129 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nbd.2010.08.020","volume":"41","author":"TS Anekonda","year":"2011","unstructured":"Anekonda, T. S. et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol. Dis. 41, 62\u201370 (2011).","journal-title":"Neurobiol. Dis."},{"key":"BFnrd3869_CR47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jep.2006.12.015","volume":"111","author":"N Li","year":"2007","unstructured":"Li, N., Liu, B., Dluzen, D. E. & Jin, Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J. Ethnopharmacol. 111, 458\u2013463 (2007).","journal-title":"J. Ethnopharmacol."},{"key":"BFnrd3869_CR48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2119\/molmed.2010.00180","volume":"17","author":"D Paris","year":"2011","unstructured":"Paris, D. et al. Selective antihypertensive dihydropyridines lower A\u03b2 accumulation by targeting both the production and the clearance of A\u03b2 across the blood\u2013brain barrier. Mol. Med. 17, 149\u2013162 (2011).","journal-title":"Mol. Med."},{"key":"BFnrd3869_CR49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1248\/bpb.30.698","volume":"30","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki, K. et al. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with \u03b2-amyloid in rats. Biol. Pharm. Bull. 30, 698\u2013701 (2007).","journal-title":"Biol. Pharm. Bull."},{"key":"BFnrd3869_CR50","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1242\/dmm.006841","volume":"4","author":"PF Copenhaver","year":"2011","unstructured":"Copenhaver, P. F. et al. A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. Dis. Model. Mech. 4, 634\u2013648 (2011).","journal-title":"Dis. Model. Mech."},{"key":"BFnrd3869_CR51","first-page":"CD000147","volume":"2002","author":"JM Lopez-Arrieta","year":"2002","unstructured":"Lopez-Arrieta, J. M. & Birks, J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 2002, CD000147 (2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrd3869_CR52","first-page":"175","volume":"28","author":"RJ Branconnier","year":"1992","unstructured":"Branconnier, R. J., Branconnier, M. E., Walshe, T. M., McCarthy, C. & Morse, P. A. Blocking the Ca2+-activated cytotoxic mechanisms of cholinergic neuronal death: a novel treatment strategy for Alzheimer's disease. Psychopharmacol. Bull. 28, 175\u2013181 (1992).","journal-title":"Psychopharmacol. Bull."},{"key":"BFnrd3869_CR53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-199611040-00001","volume":"11","author":"FJ Morich","year":"1996","unstructured":"Morich, F. J. et al. Nimodipine in the treatment of probable Alzheimer's disease \u2014 results of two multicentre trials. Clin. Drug Invest. 11, 185\u2013195 (1996).","journal-title":"Clin. Drug Invest."},{"key":"BFnrd3869_CR54","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/gps.2638","volume":"26","author":"SP Kennelly","year":"2011","unstructured":"Kennelly, S. P. et al. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug nilvadipine: results from a 6-week open label study. Int. J. Geriatr. Psychiatry 26, 1038\u20131045 (2011).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrd3869_CR55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/gps.2735","volume":"27","author":"S Kennelly","year":"2012","unstructured":"Kennelly, S. et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients \u2014 an open-label trial. Int. J. Geriatr. Psychiatry 27, 415\u2013422 (2012).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrd3869_CR56","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archneur.63.5.noc60013","volume":"63","author":"AS Khachaturian","year":"2006","unstructured":"Khachaturian, A. S. et al. Antihypertensive medication use and incident Alzheimer disease \u2014 the Cache County study. Arch. Neurol. 63, 686\u2013692 (2006).","journal-title":"Arch. Neurol."},{"key":"BFnrd3869_CR57","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","volume":"162","author":"F Forette","year":"2002","unstructured":"Forette, F. et al. The prevention of dementia with antihypertensive treatment. Arch. Intern. Med. 162, 2046\u20132052 (2002).","journal-title":"Arch. Intern. Med."},{"key":"BFnrd3869_CR58","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1212\/WNL.0b013e3181ffe4f6","volume":"75","author":"EMC Schrijvers","year":"2010","unstructured":"Schrijvers, E. M. C. et al. Insulin metabolism and the risk of Alzheimer disease \u2014 the Rotterdam study. Neurology 75, 1982\u20131987 (2010).","journal-title":"Neurology"},{"key":"BFnrd3869_CR59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney, A. M. et al. Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224\u2013243 (2010).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3869_CR60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0031-9384(04)00348-8","volume":"83","author":"U Stockhorst","year":"2004","unstructured":"Stockhorst, U., de Fries, D., Steingrueber, H. J. & Scherbaum, W. A. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83, 47\u201354 (2004).","journal-title":"Physiol. Behav."},{"key":"BFnrd3869_CR61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/REVNEURO.2005.16.3.181","volume":"16","author":"C Holscher","year":"2005","unstructured":"Holscher, C. Development of \u03b2-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev. Neurosci. 16, 181\u2013212 (2005).","journal-title":"Rev. Neurosci."},{"key":"BFnrd3869_CR62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2004.02.049","volume":"490","author":"S Hoyer","year":"2004","unstructured":"Hoyer, S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115\u2013125 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR63","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.brainresrev.2007.09.001","volume":"56","author":"L Li","year":"2007","unstructured":"Li, L. & H\u00f6lscher, C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384\u2013402 (2007).","journal-title":"Brain Res. Rev."},{"key":"BFnrd3869_CR64","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1530-0277.2007.00450.x","volume":"31","author":"AC Cohen","year":"2007","unstructured":"Cohen, A. C., Tong, M., Wands, J. R. & de la Monte, S. M. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin. Exp. Res. 31, 1558\u20131573 (2007).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"BFnrd3869_CR65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.02.047","volume":"490","author":"P van Dam","year":"2004","unstructured":"van Dam, P. & Aleman, A. Insulin-like growth factor-I, cognition and brain aging. Eur. J. Pharmacol. 490, 87\u201395 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR66","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db07-0171","volume":"56","author":"ZG Li","year":"2007","unstructured":"Li, Z. G., Zhang, W. & Sima, A. A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56, 1817\u20131824 (2007).","journal-title":"Diabetes"},{"key":"BFnrd3869_CR67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2004.02.050","volume":"490","author":"E Carro","year":"2004","unstructured":"Carro, E. & Torres, A. I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 490, 127\u2013133 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.02.048","volume":"490","author":"GS Watson","year":"2004","unstructured":"Watson, G. S. & Craft, S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 490, 97\u2013113 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","volume":"490","author":"WQ Zhao","year":"2004","unstructured":"Zhao, W. Q. Chen, H., Quon, M. J. & Alkon, D. L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490, 71\u201381 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR70","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger, M. A. et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-\u03b2 in memory-impaired older adults. J. Alzheimers Dis. 13, 323\u2013331 (2008).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/gps.2089","volume":"24","author":"OI Okereke","year":"2008","unstructured":"Okereke, O. I. et al. A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int. J. Geriatr. Psychiatry 24, 177\u2013182 (2008).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrd3869_CR72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"MA Reger","year":"2008","unstructured":"Reger, M. A. et al. Intranasal insulin improves cognition and modulates \u03b2-amyloid in early AD. Neurology 70, 440\u2013448 (2008).","journal-title":"Neurology"},{"key":"BFnrd3869_CR73","first-page":"51","volume":"68","author":"LD Baker","year":"2010","unstructured":"Baker, L. D. et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68, 51\u201357 (2010).","journal-title":"Arch. Neurol."},{"key":"BFnrd3869_CR74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft, S. et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29\u201338 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrd3869_CR75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/B978-0-12-381517-0.00013-8","volume-title":"Vitamins and Hormones: Incretins and Insulin Secretion","author":"C Holscher","year":"2010","unstructured":"Holscher, C. in Vitamins and Hormones: Incretins and Insulin Secretion (ed. Litwack, G.) 331\u2013354 (Academic Press, 2010)."},{"key":"BFnrd3869_CR76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jnr.10611","volume":"72","author":"T Perry","year":"2003","unstructured":"Perry, T. et al. Glucagon-like peptide-1 decreases endogenous amyloid-\u03b2 peptide (A\u03b2) levels and protects hippocampal neurons from death induced by A\u03b2 and iron. J. Neurosci. Res. 72, 603\u2013612 (2003).","journal-title":"J. Neurosci. Res."},{"key":"BFnrd3869_CR77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2011.11.005","volume":"674","author":"L Li","year":"2012","unstructured":"Li, L. et al. (Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur. J. Pharmacol. 674, 280\u2013286 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd3869_CR78","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry, T. et al. A novel neutrotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958\u2013966 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3869_CR79","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.neuroscience.2010.08.028","volume":"170","author":"XH Wang","year":"2010","unstructured":"Wang, X. H. et al. Val8-glucagon-like peptide-1 protects against A\u03b21\u201340-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170, 1239\u20131248 (2010).","journal-title":"Neuroscience"},{"key":"BFnrd3869_CR80","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde, R. et al. A\u03b242-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940\u2013946 (2006).","journal-title":"EMBO Rep."},{"key":"BFnrd3869_CR81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neurobiolaging.2010.02.014","volume":"33","author":"S Gengler","year":"2012","unstructured":"Gengler, S., McClean, P., McCurtin, R., Gault, V. & Holscher, C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP\/PS1 mice. Neurobiol. Aging 33, 265\u2013276 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3869_CR82","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean, P. L., Parthsarathy, V., Faivre, E. & Holscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587\u20136594 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrd3869_CR83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jnr.22565","volume":"89","author":"A Hamilton","year":"2011","unstructured":"Hamilton, A., Patterson, S., Porter, D., Gault, V. A. & Holscher, C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481\u2013489 (2011).","journal-title":"J. Neurosci. Res."},{"key":"BFnrd3869_CR84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","volume":"18","author":"AJ Kastin","year":"2002","unstructured":"Kastin, A. J., Akerstrom, V. & Pan, W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood\u2013brain barrier. J. Mol. Neurosci. 18, 7\u201314 (2002).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrd3869_CR85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin, A. J. & Akerstrom, V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313\u2013318 (2003).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"BFnrd3869_CR86","doi-asserted-by":"crossref","unstructured":"McClean, P., Pathasarthy, V., Faivre, E. & H\u00f6lscher, C. Liraglutide, a novel GLP-1 analogue, prevents the impairment of learning and LTP in an APP\/PS-1 mouse model of Alzheimer's disease. Session 556.11, Poster K20 (Society for Neuroscience 40th Annual Meeting, San Diego, California; 2010).","DOI":"10.1016\/j.regpep.2010.07.102"},{"key":"BFnrd3869_CR87","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606\u20131616 (2009).","journal-title":"Lancet"},{"key":"BFnrd3869_CR88","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","volume":"487","author":"G Forloni","year":"2001","unstructured":"Forloni, G., Colombo, L., Girola, L., Tagliavini, F. & Salmona, M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487, 404\u2013407 (2001).","journal-title":"FEBS Lett."},{"key":"BFnrd3869_CR89","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/glia.20051","volume":"48","author":"JK Ryu","year":"2004","unstructured":"Ryu, J. K., Franciosi, S., Sattayaprasert, P., Kim, S. U. & McLarnon, J. G. Minocycline inhibits neuronal death and glial activation induced by \u03b2-amyloid peptide in rat hippocampus. Glia 48, 85\u201390 (2004).","journal-title":"Glia"},{"key":"BFnrd3869_CR90","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1523\/JNEUROSCI.4371-06.2007","volume":"27","author":"R Fan","year":"2007","unstructured":"Fan, R. et al. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 27, 3057\u20133063 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrd3869_CR91","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/j.1471-4159.2009.06096.x","volume":"109","author":"M Garcia-Alloza","year":"2009","unstructured":"Garcia-Alloza, M. et al. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem. 109, 1636\u20131647 (2009).","journal-title":"J. Neurochem."},{"key":"BFnrd3869_CR92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/pri.3.2.8820","volume":"3","author":"W Noble","year":"2009","unstructured":"Noble, W., Garwood, C. J. & Hanger, D. P. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3, 78\u201383 (2009).","journal-title":"Prion"},{"key":"BFnrd3869_CR93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3233\/JAD-2010-100204","volume":"21","author":"A Parachikova","year":"2010","unstructured":"Parachikova, A., Vasilevko, V., Cribbs, D. H., LaFerla, F. M. & Green, K. N. Reductions in amyloid-\u03b2-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J. Alzheimers Dis. 21, 527\u2013542 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR94","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1734-1140(11)70504-7","volume":"63","author":"ZY Cai","year":"2011","unstructured":"Cai, Z. Y., Zhao, Y., Yao, S. T. & Zhao, B. Increases in \u03b2-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-\u03baB pathway activation. Pharmacol. Rep. 63, 381\u2013391 (2011).","journal-title":"Pharmacol. Rep."},{"key":"BFnrd3869_CR95","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000285514","volume":"7","author":"AC Cuello","year":"2010","unstructured":"Cuello, A. C. et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener. Dis. 7, 96\u201398 (2010).","journal-title":"Neurodegener. Dis."},{"key":"BFnrd3869_CR96","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/glia.20338","volume":"53","author":"TJ Seabrook","year":"2006","unstructured":"Seabrook, T. J., Jiang, L. Y., Maier, M. & Lemere, C. A. Minocycline affects microglia activation, A\u03b2 deposition, and behavior in APP-tg mice. Glia 53, 776\u2013782 (2006).","journal-title":"Glia"},{"key":"BFnrd3869_CR97","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/glia.20726","volume":"56","author":"TM Malm","year":"2008","unstructured":"Malm, T. M. et al. Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. Glia 56, 1767\u20131779 (2008).","journal-title":"Glia"},{"key":"BFnrd3869_CR98","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659\u2013661 (2008).","journal-title":"FASEB J."},{"key":"BFnrd3869_CR99","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","volume":"6","author":"PH Gordon","year":"2007","unstructured":"Gordon, P. H. et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a Phase III randomised trial. Lancet Neurol. 6, 1045\u20131053 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrd3869_CR100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/01.WNL.0000049936.85487.7A","volume":"60","author":"RM Bonelli","year":"2003","unstructured":"Bonelli, R. M., Heuberger, C. & Reisecker, F. Minocycline for Huntington's disease: an open label study. Neurology 60, 883\u2013884 (2003).","journal-title":"Neurology"},{"key":"BFnrd3869_CR101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","volume":"19","author":"RM Bonelli","year":"2004","unstructured":"Bonelli, R. M., Hodl, A. K., Hofmann, P. & Kapfhammer, H. P. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19, 337\u2013342 (2004).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"BFnrd3869_CR102","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas, M., Ashizawa, T. & Jankovic, J. Minocycline in Huntington's disease: a pilot study. Mov. Disord. 19, 692\u2013695 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrd3869_CR103","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","volume":"25","author":"H Schwarz","year":"2010","unstructured":"Schwarz, H. et al. A futility study of minocycline in Huntington's disease. Mov. Disord. 25, 2219\u20132224 (2010).","journal-title":"Mov. Disord."},{"key":"BFnrd3869_CR104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/WNF.0b013e3181342f32","volume":"31","author":"K Kieburtz","year":"2008","unstructured":"Kieburtz, K. et al. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 31, 141\u2013150 (2008).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrd3869_CR105","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1073\/pnas.0437937100","volume":"100","author":"AB Goodman","year":"2003","unstructured":"Goodman, A. B. & Pardee, A. B. Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 2901\u20132905 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3869_CR106","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1460-9568.2004.03563.x","volume":"20","author":"JPT Corcoran","year":"2004","unstructured":"Corcoran, J. P. T., So, P. L. & Maden, M. Disruption of the retinoid signalling pathway causes a deposition of amyloid \u03b2 in the adult rat brain. Eur. J. Neurosci. 20, 896\u2013902 (2004).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrd3869_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.01.008","volume":"23","author":"M Husson","year":"2006","unstructured":"Husson, M. et al. Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in \u03b2-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol. Dis. 23, 1\u201310 (2006).","journal-title":"Neurobiol. Dis."},{"key":"BFnrd3869_CR108","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1523\/JNEUROSCI.3153-08.2008","volume":"28","author":"Y Ding","year":"2008","unstructured":"Ding, Y. et al. Retinoic acid attenuates \u03b2-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J. Neurosci. 28, 11622\u201311634 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrd3869_CR109","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1096\/fj.08-121392","volume":"23","author":"F Tippmann","year":"2009","unstructured":"Tippmann, F., Hundt, J., Schneider, A., Endres, K. & Fahrenholz, F. Up-regulation of the \u03b1-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23, 1643\u20131654 (2009).","journal-title":"FASEB J."},{"key":"BFnrd3869_CR110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/j.1460-9568.2010.07426.x","volume":"32","author":"CI Jarvis","year":"2010","unstructured":"Jarvis, C. I. et al. Retinoic acid receptor-\u03b1 signalling antagonizes both intracellular and extracellular amyloid-\u03b2 production and prevents neuronal cell death caused by amyloid-\u03b2. Eur. J. Neurosci. 32, 1246\u20131255 (2010).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrd3869_CR111","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1248\/bpb.32.1307","volume":"32","author":"K Kawahara","year":"2009","unstructured":"Kawahara, K. et al. Oral administration of synthetic retinoid am80 (tamibarotene) decreases brain \u03b2-amyloid peptides in APP23 mice. Biol. Pharm. Bull. 32, 1307\u20131309 (2009).","journal-title":"Biol. Pharm. Bull."},{"key":"BFnrd3869_CR112","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","volume":"335","author":"PE Cramer","year":"2012","unstructured":"Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models. Science 335, 1503\u20131506 (2012).","journal-title":"Science"},{"key":"BFnrd3869_CR113","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd3869_CR114","first-page":"787","volume":"7","author":"G Melino","year":"1996","unstructured":"Melino, G. et al. Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines. Cell Growth Differ. 7, 787\u2013796 (1996).","journal-title":"Cell Growth Differ."},{"key":"BFnrd3869_CR115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ydbio.2006.06.027","volume":"298","author":"PL So","year":"2006","unstructured":"So, P. L. et al. Interactions between retinoic acid, nerve growth factor and sonic hedgehog signalling pathways in neurite outgrowth. Dev. Biol. 298, 167\u2013175 (2006).","journal-title":"Dev. Biol."},{"key":"BFnrd3869_CR116","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ydbio.2008.11.018","volume":"326","author":"M Goncalves","year":"2009","unstructured":"Goncalves, M. et al. Sequential RAR\u03b2 and \u03b1 signalling in vivo can induce adult forebrain neural progenitor cells to differentiate into neurons through Shh and FGF signalling pathways. Dev. Biol. 326, 305\u2013313 (2009).","journal-title":"Dev. Biol."},{"key":"BFnrd3869_CR117","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1586\/ern.09.86","volume":"9","author":"HP Lee","year":"2009","unstructured":"Lee, H. P. et al. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev Neurother. 9, 1615\u20131621 (2009).","journal-title":"Expert Rev Neurother."},{"key":"BFnrd3869_CR118","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/156720509788486581","volume":"6","author":"K Shudo","year":"2009","unstructured":"Shudo, K., Fukasawa, H., Nakagomi, M. & Yamagata, N. Towards retinoid therapy for Alzheimer's disease. Curr. Alzheimer Res. 6, 302\u2013311 (2009).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrd3869_CR119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0090-9556(25)08301-1","volume":"22","author":"EU Eisenhardt","year":"1994","unstructured":"Eisenhardt, E. U. & Bickel, M. H. Kinetics of tissue distribution and elimination of retinoid drugs in the rat. I. Acitretin. Drug Metab. Dispos. 22, 26\u201330 (1994).","journal-title":"Drug Metab. Dispos."},{"key":"BFnrd3869_CR120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3956(02)00085-7","volume":"37","author":"RD Nebes","year":"2003","unstructured":"Nebes, R. D. et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J. Psychiatr. Res. 37, 99\u2013108 (2003).","journal-title":"J. Psychiatr. Res."},{"key":"BFnrd3869_CR121","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00213-008-1101-3","volume":"198","author":"AB Scholey","year":"2008","unstructured":"Scholey, A. B. et al. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology 198, 127\u2013139 (2008).","journal-title":"Psychopharmacology"},{"key":"BFnrd3869_CR122","first-page":"CD004034","volume":"2009","author":"B McGuinness","year":"2009","unstructured":"McGuinness, B., Todd, S., Passmore, P. & Bullock, R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, CD004034 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrd3869_CR123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1749-6632.2010.05726.x","volume":"1207","author":"PB Gorelick","year":"2010","unstructured":"Gorelick, P. B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann. NY Acad. Sci. 1207, 155\u2013162 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrd3869_CR124","first-page":"CD006378","volume":"2012","author":"D Jaturapatporn","year":"2012","unstructured":"Jaturapatporn, D., Isaac, M., McCleery, J. & Tabet, N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev. 2012, CD006378 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrd3869_CR125","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes, C. et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768\u2013774 (2009).","journal-title":"Neurology"},{"key":"BFnrd3869_CR126","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2010.01.017","volume":"77","author":"YM Chen","year":"2010","unstructured":"Chen, Y. M., Chen, H. H., Lan, J. L. & Chen, D. Y. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine 77, 366\u2013367 (2010).","journal-title":"Joint Bone Spine"},{"key":"BFnrd3869_CR127","doi-asserted-by":"crossref","first-page":"e12244","DOI":"10.1371\/journal.pone.0012244","volume":"5","author":"AD Smith","year":"2010","unstructured":"Smith, A. D. et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 5, e12244 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrd3869_CR128","first-page":"CD007204","volume":"2009","author":"S Krishnan","year":"2009","unstructured":"Krishnan, S., Cairns, R. & Howard, R. Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev. 2009, CD007204 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrd3869_CR129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/path.2449","volume":"217","author":"MA Wozniak","year":"2009","unstructured":"Wozniak, M. A., Mee, A. P. & Itzhaki, R. F. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J. Pathol. 217, 131\u2013138 (2009).","journal-title":"J. Pathol."},{"key":"BFnrd3869_CR130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-2008-13405","volume":"13","author":"RF Itzhaki","year":"2008","unstructured":"Itzhaki, R. F. & Wozniak, M. A. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J. Alzheimers Dis. 13, 393\u2013405 (2008).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR131","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/gps.1964","volume":"23","author":"A Macdonald","year":"2008","unstructured":"Macdonald, A. et al. A feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriatr. Psychiatry 23, 704\u2013711 (2008).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrd3869_CR132","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","volume":"70","author":"H Hampel","year":"2009","unstructured":"Hampel, H. et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70, 922\u2013931 (2009).","journal-title":"J. Clin. Psychiatry"},{"key":"BFnrd3869_CR133","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd2959","volume":"8","author":"KR Brunden","year":"2009","unstructured":"Brunden, K. R., Trojanowski, J. Q. & Lee, V. M. Y. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Rev. Drug Discov. 8, 783\u2013793 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3869_CR134","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","volume":"60","author":"A Gupta","year":"2011","unstructured":"Gupta, A., Bisht, B. & Dey, C. S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60, 910\u2013920 (2011).","journal-title":"Neuropharmacology"},{"key":"BFnrd3869_CR135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","volume":"24","author":"CC Hsu","year":"2011","unstructured":"Hsu, C. C., Wahlqvist, M. L., Lee, M. S. & Tsai, H. N. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J. Alzheimers Dis. 24, 485\u2013493 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3869_CR136","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1532-5415.2004.52109.x","volume":"52","author":"MB Loeb","year":"2004","unstructured":"Loeb, M. B. et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatr. Soc. 52, 381\u2013387 (2004).","journal-title":"J. Am. Geriatr. Soc."},{"key":"BFnrd3869_CR137","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"AS Fleisher","year":"2011","unstructured":"Fleisher, A. S. et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77, 1263\u20131271 (2011).","journal-title":"Neurology"},{"key":"BFnrd3869_CR138","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"M Gold","year":"2010","unstructured":"Gold, M. et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled Phase III study. Dementia Geriatr. Cognitive Disord. 30, 131\u2013146 (2010).","journal-title":"Dementia Geriatr. Cognitive Disord."},{"key":"BFnrd3869_CR139","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"T Sato","year":"2011","unstructured":"Sato T. et al. Efficacy of PPAR-\u03b3 agonist pioglitazone in mild Alzheimer's disease. Neurobiol. Aging 32, 1626\u20131633 (2011).","journal-title":"Neurobiol. Aging"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd3869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3869","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T07:06:33Z","timestamp":1745132793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":139,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFnrd3869"],"URL":"https:\/\/doi.org\/10.1038\/nrd3869","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}